Your browser is no longer supported. Please, upgrade your browser.
GNFT Genfit SA daily Stock Chart
Genfit SA
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand38.84M Perf Week3.45%
Market Cap209.73M Forward P/E- EPS next Y- Insider Trans- Shs Float38.84M Perf Month-74.25%
Income- PEG- EPS next Q- Inst Own3.37% Short Float0.31% Perf Quarter-65.43%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.06 Perf Half Y-65.61%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-77.68%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.15 - 24.85 Perf YTD-72.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.27% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low4.85% ATR0.87
Employees194 Current Ratio- Sales Q/Q1354.40% Oper. Margin- RSI (14)24.35 Volatility4.69% 6.25%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.60 Prev Close5.26
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume113.20K Price5.40
Recom- SMA20-32.70% SMA50-61.74% SMA200-66.09% Volume180,910 Change2.66%
May-13-20Downgrade Kepler Buy → Reduce
May-12-20Downgrade H.C. Wainwright Buy → Neutral $46 → $11
May-12-20Downgrade Barclays Overweight → Equal Weight $55 → $14
Oct-29-19Reiterated B. Riley FBR Buy $52 → $43
Jun-25-19Initiated Stifel Hold
Apr-24-19Initiated SVB Leerink Outperform $58
Apr-22-19Initiated Barclays Overweight
May-26-20 01:19PM  
May-14-20 05:31PM  
May-12-20 02:20PM  
May-11-20 05:52PM  
Apr-17-20 08:43AM  
Apr-11-20 02:32AM  
Mar-30-20 06:06PM  
Mar-04-20 04:26PM  
Mar-03-20 02:20PM  
Mar-02-20 05:35PM  
Feb-26-20 03:06PM  
Feb-25-20 03:10PM  
Feb-24-20 04:45PM  
Feb-21-20 11:57AM  
Feb-17-20 05:35AM  
Jan-08-20 07:37AM  
Jan-02-20 09:08AM  
Dec-22-19 05:32PM  
Dec-10-19 03:36PM  
Nov-26-19 08:06AM  
Nov-18-19 02:57AM  
Nov-09-19 02:58PM  
Oct-03-19 09:29AM  
Aug-19-19 02:45PM  
Aug-13-19 02:10AM  
Jul-08-19 04:32AM  
Jun-29-19 06:18PM  
Jun-25-19 07:15AM  
Jun-24-19 04:31PM  
Jun-17-19 01:50PM  
May-09-19 02:00PM  
May-02-19 03:43PM  
May-01-19 11:12AM  
Apr-30-19 10:24AM  
Apr-25-19 10:11AM  
Apr-24-19 09:04AM  
Apr-15-19 04:26PM  
Apr-07-19 02:00PM  
Apr-02-19 06:34PM  
Mar-27-19 06:13PM  
Mar-24-19 05:16PM  
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.